Ann: Appendix 4C - quarterly, page-16

valueadd:  "If it is proven clinically to be so then the worth of the IP would be very hard to calculate."

valueadd/others:  I assume that we (more or less) are all invested here because we hope/expect that IMU will be able to clinically prove up the B Cell platform (with very good to hopefully excellent effectiveness).  Why else would one be invested here - certainly not for failure??

And then, just in my view again, the current share-price will (by then in hindsight) look like a kind of 'sad joke' perhaps??  For sure, IMU will be worth much,  much more than the current measly market cap.

Naturally, we all must be FULLY aware that investing in biotech is very HIGH RISK with corresponding either high reward or massive loss.

Lastly, we should also hope for a great outcome mainly by keeping in mind that the many cancer sufferers worldwide deserve a better option for treatment.

All the best to all IMU holders.  Enjoy the rest of the week ahead.

wasa